VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Hadassah Medical Center

Status: Withdrawn

Conditions: Preterm Infants Developing Normally; Preterm Infants With White Matter Damage

Study type: Observational

Funder types: Other

Identifiers

NCT00564161

606060-HMO-CTIL

Details and patient eligibility

About

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Sex: All

Ages: 25 to 40 weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Preterm infants undergoing lumbar puncture.

Exclusion criteria

• Preterm with IVH or known infection or meningitis.

Trial design

0 participants in 2 patient groups

1

2